Novo Nordisk A/S (NYSE:NVO) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC trimmed its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 31.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 36,296 shares of the company's stock after selling 16,500 shares during the period. Yousif Capital Management LLC's holdings in Novo Nordisk A/S were worth $2,520,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in NVO. Center for Financial Planning Inc. lifted its holdings in shares of Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after buying an additional 123 shares during the period. Strategic Investment Solutions Inc. IL lifted its holdings in Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after acquiring an additional 300 shares during the last quarter. Park Square Financial Group LLC bought a new position in shares of Novo Nordisk A/S during the 4th quarter valued at about $29,000. Transce3nd LLC acquired a new position in shares of Novo Nordisk A/S in the 4th quarter worth approximately $33,000. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new position in shares of Novo Nordisk A/S in the 4th quarter worth approximately $39,000. 11.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Saturday. BMO Capital Markets reiterated a "market perform" rating and set a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. BNP Paribas initiated coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating on the stock. Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Finally, Stifel Nicolaus lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of "Hold" and a consensus price target of $112.00.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $79.90 on Friday. The business's 50-day moving average is $67.30 and its 200-day moving average is $79.63. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The company has a market capitalization of $358.57 billion, a price-to-earnings ratio of 24.29, a P/E/G ratio of 0.90 and a beta of 0.66. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The business had revenue of $11.87 billion for the quarter. Equities research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.